NCT03972930Active, not recruitingPhase 2
Hypofractionated Radiotherapy for Soft Tissue Sarcomas
Phase 2 Trial of Hypofractionated Radiotherapy for Soft Tissue Sarcomas
Source: ClinicalTrials.gov · Last updated 2 Jul 2026
Brief summary (registry, in English)
One of the main challenges in treating sarcomas with radiation is the toxicity to normal structures around the sarcoma. Early reports suggest Hypofractionated Radiotherapy will be safe and effective for treatment of soft tissue sarcomas. However, given the rarity of this disease, the diversity of histological sub-types, and the variety of locations where these can occur (anywhere in the body), more data is needed to provide understanding of the safety and efficacy of hypofractionated radiotherapy for treatment of this disease. The hypothesis is that by using hypofractionated radiotherapy, highly conformal high dose radiation can be delivered to soft tissue sarcomas, while respecting established normal tissue constraints and that local control rates will be greater than historical rates reported with conventional fractionation. Eligible participants with biopsy proven soft tissue sarcoma will be on study for up to 60 months.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 48 (actual)
- First submitted
- 31 May 2019
- Start date
- 11 Jun 2019
- Primary completion date
- 28 Nov 2024
- Lead sponsor
- University of Wisconsin, Madison
- Diseases
- Sarcoma
- NCT number
- NCT03972930
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 48
- From 11 Jun 2019 to the primary completion date, 28 Nov 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Unable to undergo imaging or positioning necessary for radiotherapy planning
- Prior radiation therapy in the field that, at the discretion of the treating physician, prevents safe delivery of hypofractionated radiotherapy.
Other illness
- Chemotherapy or systemic anti-cancer treatment within the preceding two weeks
Other
- Pregnant
Who the study is looking for
- Biopsy proven soft tissue sarcoma, either localized and inoperable/unresectable or metastatic, that is deemed by the treating physician to be targetable with hypofractionated radiotherapy.
- Participant refuses surgery or is aware that surgery is not recommended for them
- Karnofsky performance status \> 60
- Able to understand and sign an informed consent form
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Wisconsin Coordinator of this site? Confirm its status | Madison | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.